05/16/2017 The European Patent Office has upheld the grantof a European patent owned by Shire relating to its Factor VIII ADVATE franchise (EP 2 318 050 B1). Novo-Nordisk, Shire’s competitor in the hemophilia space, challenged the patent on four separate grounds. However, the EPO sided with Shire’s position as to the patent’s validity, and ruled in favor of Shire on all grounds, following oral proceedings held on May 16, 2017. The EP 050 patent is part of Shire’s IP portfolio relating to its FVIII ADVATE franchise, and this win will allow SHIRE to continue to protect a key component of its hemophilia business in the EU.
The RMMS team included Paul Molino, Katie Boda, Thomas Ehrich, Lauren Lesko and Heinz Salmen.